Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 65 points (-0.4%) at 15,111 as of Friday, June 14, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 2,604 issues advancing vs. 474 declining with 57 unchanged. The Diversified Services industry currently sits down 0.46 versus the S&P 500, which is down 0.25. On the negative front, top decliners within the industry include Alliance Data Systems Corporation ( ADS), down 1.10, H&R Block ( HRB), down 0.99, Hertz Global Holdings ( HTZ), down 0.79 and Visa ( V), down 0.60. A company within the industry that increased today was New Oriental Education & Technology Group I ( EDU), up 1.73. TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today: 4. Myriad Genetics ( MYGN) is one of the companies pushing the Diversified Services industry lower today. As of noon trading, Myriad Genetics is down $2.43 (-7.6%) to $29.58 on heavy volume Thus far, 12.6 million shares of Myriad Genetics exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $27.83-$31.19 after having opened the day at $30.12 as compared to the previous trading day's close of $32.01. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics has a market cap of $2.7 billion and is part of the services sector. The company has a P/E ratio of 21.6, above the S&P 500 P/E ratio of 17.7. Shares are up 17.5% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Myriad Genetics a buy, 1 analyst rates it a sell, and 5 rate it a hold. TheStreet Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Myriad Genetics Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.